References
1. Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 74(3), 229-263.
2. Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M.,... & Soerjomataram, I. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. The breast, 66, 15-23.).
3. Dyba, T., Randi, G., Bray, F., Martos, C., Giusti, F., Nicholson, N.,... & Bettio, M. (2021). The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. European Journal of Cancer, 157, 308-347.
4. Bosch, G., Posso, M., Louro, J., Roman, M., Porta, M., Castells, X., & Macià, F. (2022). Impact of the COVID-19 pandemic on breast cancer screening indicators in a Spanish population-based program: a cohort study. Elife, 11, e77434.
5. Wilkinson, L., & Gathani, T. (2022). Understanding breast cancer as a global health concern. The British journal of radiology, 95(1130), 20211033.
6. da Costa Vieira, R. A., Biller, G., Uemura, G., Ruiz, C. A., & Curado, M. P. (2017). Breast cancer screening in developing countries. Clinics, 72(4), 244-253.
7. Pesapane, F., Downey, K., Rotili, A., Cassano, E., & Koh, D. M. (2020). Imaging diagnosis of metastatic breast cancer. Insights into imaging, 11 (1), 79.
8. Roy, M., Fowler, A. M., Ulaner, G. A., & Mahajan, A. (2023). Molecular classification of breast cancer. PET clinics, 18(4), 441-458.
9. Barba, D., Leon-Sosa, A., Lugo, P., Suquillo, D., Torres, F., Surre, F.,... & Caicedo, A. (2021). Breast cancer, screening and diagnostic tools: All you need to know. Critical reviews in oncology/hematology, 157, 103174.
10. Beňačka, R., Szabóová, D., Guľašová, Z., Hertelyová, Z., & Radoňák, J. (2022). Classic and new markers in diagnostics and classification of breast cancer. Cancers, 14(21), 5444
11. Turashvili, G., & Brogi, E. (2017). Tumor heterogeneity in breast cancer. Frontiers in medicine, 4, 227;
12. Wolff, A. C., Somerfield, M. R., Dowsett, M., Hammond, M. E. H., Hayes, D. F., McShane, L. M.,... & Allison, K. H. (2023). Human epidermal growth factor receptor 2 testing in breast cancer: ASCO–College of American Pathologists Guideline Update. Journal of Clinical Oncology, 41(22), 3867-3872.
13. Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L.,... & Wolff, A. C. (2020). Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. Journal of Clinical Oncology, 38(12), 1346-1366.
14. Khan, M. Z. I., Uzair, M., Nazli, A., & Chen, J. Z. (2022). An overview on Estrogen receptors signaling and its ligands in breast cancer. European journal of medicinal chemistry, 241, 114658.;
15. Clusan, L., Le Goff, P., Flouriot, G., & Pakdel, F. (2021). A closer look at estrogen receptor mutations in breast cancer and their implications for estrogen and antiestrogen responses. International journal of molecular sciences, 22(2), 756.
16. Almeida, C. F., Oliveira, A., Ramos, M. J., Fernandes, P. A., Teixeira, N., & Amaral, C. (2020). Estrogen receptor-positive (ER+) breast cancer treatment: Are multi-target compounds the next promising approach?. Biochemical Pharmacology, 177, 113 989.
17. Rakha, E. A., Chmielik, E., Schmitt, F. C., Tan, P. H., Quinn, C. M., & Gallagy, G. (2022). Assessment of predictive biomarkers in breast cancer: challenges and updates. Pathobiology, 89(5), 263-277
18. Nicolini, A., Ferrari, P., & Duffy, M. J. (2018, October). Prognostic and predictive biomarkers in breast cancer: Past, present and future. In Seminars in cancer biology (Vol. 52, pp. 56-73). Academic Press.
19. Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020). Overcoming endocrine resistance in breast cancer. Cancer cell, 37(4), 496-513.)
20. Krystel-Whittemore, M., Tan, P. H., & Wen, H. Y. (2024). Predictive and prognostic biomarkers in breast tumours. Pathology, 56(2), 186-191.
21. Boonyaratanakornkit, V., Hamilton, N., Márquez-Garbán, D. C., Pateetin, P., McGowan, E. M., & Pietras, R. J. (2018). Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. Molecular and cellular endocrinology, 466, 51-72.
22. Tarighati, E., Keivan, H., & Mahani, H. (2023). A review of prognostic and predictive biomarkers in breast cancer. Clinical and experimental medicine, 23(1), 1-16.).
23. Neves Rebello Alves, L., Dummer Meira, D., Poppe Merigueti, L., Correia Casotti, M., do Prado Ventorim, D., Ferreira Figueiredo Almeida, J.,... & Drumond Louro, I. (2023). Biomarkers in breast cancer: an old story with a new end. Genes, 14(7), 1364.).
24. Tarighati, E., Keivan, H., & Mahani, H. (2023). A review of prognostic and predictive biomarkers in breast cancer. Clinical and experimental medicine, 23(1), 1-16.
25. Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M.,... & Dowsett, M. (2018). Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Patho-logists clinical practice guideline focused update. Archives of pathology & laboratory medicine, 142(11), 1364-1382.
26. Harbeck, N. (2022). Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. The Breast, 62, S12-S16.
27. Martínez-Sáez, O., & Prat, A. (2021). Current and future management of HER2-positive metastatic breast cancer. JCO oncology practice, 17(10), 594-604.).
28. Stanowicka-Grada, M., & Senkus, E. (2023). Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer. Current Treatment Options in Oncology, 24(11), 1633-1650.
29. Dempsey, N., Sandoval, A., & Mahtani, R. (2023). Metastatic HER2-positive breast cancer: is there an optimal sequence of therapy?. Current treatment options in oncology, 24(9), 1120-1137.
30. [Laurinavieciene A, Zilenaite-Petrulaitiene D. Formalin-fixed paraffin-embedded sample sectioning and immunohistochemistry staining for ER, PR, Ki67, HER2, and CD8 at the National Centre of Pathology, affiliate of Vilnius University Hospital Santaros Klinikos (Vilnius, Lithuania). protocols.io. 2024. https://dx.doi.org/10.17504/protocols.io.q26g71qxqgwz/v1]
31. Update, G. (2023). Human Epidermal Gro-wth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med, 147, 993-1000.]
